Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-072 in combination with anticancer therapy in solid tumors
NCT03993379Phase 2Terminated
- Sponsor
- CytomX
- Start
- Nov 2019
- Primary completion
- May 2020
- Modality
- Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of pacmilimab in solid tumor, melanoma, sponsored by CytomX. Started Nov 2019; status: terminated.
02
Drugs
pacmilimab
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT03993379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993379.